Chemotherapy induces plasmatic antioxidant changes in pediatric patients with acute lymphoid leukemia B that correlate to disease prognosis.

Autor:	Garbim MR; Laboratory of Tumor Biology, State University of West Paraná, UNIOESTE, Francisco Beltrão, Paraná, Brazil., Broto GE; Laboratory of Tumor Biology, State University of West Paraná, UNIOESTE, Francisco Beltrão, Paraná, Brazil.; State University of Londrina, Londrina-PR, Brazil., Trigo FC; State University of Londrina, Londrina-PR, Brazil., Victorino VJ; Instituto Federal do Rio de Janeiro -IFRJ, Campus Pinheiral, Brazil., Oliveira ST; Laboratory of Tumor Biology, State University of West Paraná, UNIOESTE, Francisco Beltrão, Paraná, Brazil., Barbosa Sabatini D; State University of Londrina, Londrina-PR, Brazil., Panis C; Laboratory of Tumor Biology, State University of West Paraná, UNIOESTE, Francisco Beltrão, Paraná, Brazil.
Jazyk:	angličtina
Zdroj:	Current research in immunology [Curr Res Immunol] 2022 Sep 28; Vol. 3, pp. 228-233. Date of Electronic Publication: 2022 Sep 28 (Print Publication: 2022).
DOI:	10.1016/j.crimmu.2022.09.001
Abstrakt:	Pediatric acute lymphoid leukemias (ALL) is the most common childhood cancer, and cytotoxic chemotherapy remains the primary treatment option. Chemotherapic drugs act by oxidative stress generation, but their clinical meaning is poorly understood. During the chemotherapy schedule, this study evaluated the antioxidant profile of peripheral blood samples from 34 patients diagnosed with type B-cell ALL (B-ALL). Peripheral blood samples were collected at diagnosis (D0) and during the induction, consolidation, and maintenance phases. The plasma total antioxidant capacity (TRAP) was determined using the high-sensitivity chemiluminescence technique. Antioxidant levels were higher on D0 compared to day 7 after treatment starting (D7) in the induction phase (28.68-1194.71 μM Trolox, p = 0.0178) and in the high-risk group (age > ten years and/or with white blood cell counts and/or > 50,000 white blood cells/m3 at diagnosis) concerning low-risk patients (253.79-1194.71 μM Trolox, p = 0.0314). Reduced TRAP was also detected in patients who died compared to those who survived (392.42-1194.71 μM Trolox, p = 0.0278). Patients under consolidation (56.14-352.05 μM Trolox, p=<0.0001) and maintenance (30.48-672.99 μM Trolox, p=<0.0001) showed a significant reduction in TRAP levels compared to those from the induction phase (28.68-1390.26 μM Trolox), reaching levels similar to cured patients out of treatment (64.82-437.82 μM Trolox). These findings suggest that the variation of the total antioxidant capacity in B-ALL during chemotherapy is a parameter that correlates to some predictors of disease prognosis. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu